Enveda Biosciences Valuation, Funding & Investors

Enveda Biosciences is valued at $2B as of September 2026.

Last Enveda Biosciences valuation

$2B

Series E · Sep 2026

Last Enveda Biosciences funding round

$311M

Series E · Sep 2026

Cumulative funding Enveda Biosciences raised

$828M

across 9 funding rounds

Key investors in Enveda Biosciences

  • True Ventures
  • FPV Ventures
  • Kinnevik
  • Lux Capital
  • Premji Invest
  • Wireframe Ventures

Enveda Biosciences Overview

About Enveda Biosciences

Enveda Biosciences is a Mountain View-based biotechnology firm using AI to map chemical structures from natural sources for drug discovery. The company has built a database of over 1 million molecules from plants, microbes, and marine organisms, analyzed via mass spectrometry and machine learning. Enveda targets inflammation, oncology, and metabolic diseases, partnering with pharmaceutical companies like Bristol Myers Squibb for lead optimization.


Founded

2019

HQ

United StatesBoulder, CO

Website

enveda.com

Status

Privately held

Customer focus

B2B

Revenue model

Services

Valuation

$2B (Sep 2026)

Enveda Biosciences Valuation

Enveda Biosciences is currently valued at $2B, based on its Series E in September 2026. Read the announcement ↗

The $311M round was led by Catalio Capital Management, with participation from Digitalis Ventures, Alderline Group, ICONIQ Capital, Durable Capital Partners, FPV Ventures and 6 other investors.

Enveda Biosciences' valuation has grown 5.0x from $400M at its Series C in November 2024 to $2B in September 2026, across 3 priced rounds.

Enveda Biosciences valuation by funding round

Enveda Biosciences valuation by funding round
DateStageValuation
Sep 2026Series E$2B
Sep 2025Series D$1B
Nov 2024Series C$400M

Enveda Biosciences Funding History

Enveda Biosciences has raised a total of $828M across 9 funding rounds.

Enveda Biosciences' first fundraising round was a $5M seed round in August 2020. The most recent completed round was a $311M Series E in September 2026.

Enveda Biosciences funding rounds

Enveda Biosciences funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Sep 2026Series ECatalio Capital Management (lead); Digitalis Ventures; Alderline Group; ICONIQ Capital; Durable Capital Partners; FPV Ventures; Premji Invest; T. Rowe Price; True Ventures; Lightspeed Venture Partners; Kinnevik; Dimension Capital$311M$2BEnveda Biosciences closed a $311 million Series E financing in September 2026 led by Catalio Capital Management, with new backing from Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund, and Alderline Group, while existing investors including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital also participated. The round values Enveda at about $2 billion and is structured as venture growth financing. Proceeds are intended to advance three clinical-stage medicines into later-phase development, bring additional programs into clinical trials for inflammatory and metabolic conditions, and scale the company’s AI-enabled drug discovery platform and automated laboratory operations. Enveda is a Boulder-based clinical-stage biotechnology company using artificial intelligence to discover medicines from natural chemistry, with three programs already in human testing and total capital raised of more than $845 million before this financing.
Sep 2025Series DPremji Invest (lead); Baillie Gifford; Lingotto; Level Ventures; Lux Capital; FPV Ventures; Socium Ventures; Peakline; IA Ventures; Henry Kravis; Kinnevik; Dimension Capital$150M$1BEnveda Biosciences is a Boulder, CO-based drug discovery company founded in 2019 that uses an AI-driven platform and proprietary chemical sequencer to analyze plant and natural chemistry, decoding previously inaccessible molecules from living systems via machine learning and metabolomics to accelerate the discovery of novel small molecule therapeutics. The company targets large indications like atopic dermatitis, asthma, inflammatory bowel disease, fibrosis, and obesity, with a pipeline including sixteen preclinical programs, over a dozen development candidates, four IND-enabling programs, and one clinical program in Phase 1b for lead candidate ENV-294. On September 4, 2025, Enveda raised $150 million in an oversubscribed Series D funding round led by Premji Invest, with participation from new and existing investors including Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV Ventures, Socium Ventures, Dimension Capital, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital. This round achieved unicorn status with a $1 billion valuation and brought total funding to $517 million following a $150 million Series C closed in February 2025 that included Sanofi. The capital will accelerate product development, expand clinical programs into Phase 1b and Phase 2 trials, support multiple IND filings, grow the team beyond 200 employees, and scale global operations. Enveda has rapidly advanced from platform proof-of-concept to clinical-stage in five years, enrolling its first patient in the Phase 1b trial for ENV-294, an eczema prospect pitched for JAK-like efficacy with improved safety, while preparing other candidates like NLRP3/TL1A inhibitors and hormone mimetics. The company added former Pfizer CSO Mikael Dolsten to its board to guide commercialization. Investors highlight Enveda's unprecedented speed—generating first-in-class molecules more than fourfold faster than typical biotechs—and its potential to tap billions of years of evolutionary chemistry for transformative medicines in immunology, inflammation, and metabolic diseases.
Feb 2025Series CSanofi (lead)$20M-Enveda Biosciences, a Boulder, Colorado-based biotechnology company, develops AI-driven drug discovery platforms that harness life's chemistry, particularly metabolites from nature, to create novel small molecule therapeutics for chronic diseases. The company uses machine learning and metabolomics via its proprietary chemical sequencer to decode chemistry in living systems and accelerate discovery of first-in-class medicines. On February 26, 2025, Enveda announced a $20 million investment from Sanofi, bringing the total Series C financing to $150 million after an initial $130 million raise late in the prior year. This funding supports advancing AI-driven drug discovery to clinical trials, expanding the clinical pipeline, and enhancing discovery capabilities. Enveda has demonstrated progress with its pipeline, recently advancing ENV-294, a first-in-class oral small molecule for atopic dermatitis and asthma targeting a novel mechanism in immunology and inflammation, into clinical trials. The company aims to fill therapeutic gaps with molecules offering efficacy similar to JAK inhibitors but improved safety. Sanofi's investment, from a global leader in immunology, validates Enveda's platform, execution, and potential to redefine drug development by tapping nature's chemical diversity. This Series C extension positions Enveda to further develop its pipeline in 2025 across areas like atopic dermatitis, asthma, and more, beating industry benchmarks in discovery pace and success rates. Subsequent developments include a $150 million Series D round in September 2025 led by Premji Invest, achieving unicorn status with total funding over $500 million, to support Phase 1b/2 trials in atopic dermatitis, inflammatory bowel disease, obesity, and additional IND filings. Investors in later rounds included Baillie Gifford, Kinnevik, Lux Capital, and others, highlighting strong industry confidence in Enveda's techbio approach.
Nov 2024Series CFPV Ventures (lead); Kinnevik (lead); Baillie Gifford; Lingotto; The Nature Conservancy; Dimension Capital Management; Lux Capital; Premji Invest; True Ventures; Henry Kravis; Cresset Partners$130M$400MEnveda Biosciences, a Boulder, Colorado-based biotechnology company, closed an oversubscribed USD 130 million Series C round in November 2024, co-led by Kinnevik and FPV Ventures. Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital Management, True Ventures, Cresset Partners, The Nature Conservancy and Henry Kravis also took part, and Kinnevik committed SEK 438 million. The round brought total funding to USD 360 million, following USD 55 million raised in June 2024 and USD 51 million in April 2023. Enveda said the capital would fund multiple clinical readouts in 2025 and 2026 from a pipeline of 10 development candidates. The company was founded in 2019 and uses artificial intelligence, machine learning, metabolomics and automated laboratory workflows to turn compounds found in nature into small-molecule medicines. Its lead candidate, ENV-294, an oral anti-inflammatory agent, entered Phase 1 testing for atopic dermatitis and related inflammatory conditions in late October 2024.
Jun 2024Series BLingotto; The Nature Conservancy; Microsoft; Level Ventures; FPV Ventures; Premji Invest; True Ventures; Jazz Venture Partners; Kinnevik$55M-Enveda Biosciences, founded in 2019 and based in Boulder, Colorado, is a biotechnology company using AI-powered technologies to translate nature's chemistry into new medicines. The company builds a proprietary database called the 'library of life' by identifying, characterizing, and analyzing molecules from living organisms, addressing challenges in natural product drug discovery such as active molecule identification, structure prioritization, medicinal chemistry amenability, and material access. This platform has enabled the nomination of a sixth New Chemical Entity (NCE) development candidate. On June 14, 2024, Enveda announced a $55 million Series B2 financing round, adding to its prior $119 million combined Series B and B1 rounds from 2023, bringing total capital raised to $230 million. New investors included Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, alongside existing backers Kinnevik, True Ventures, FPV Ventures, Level Ventures, and Jazz Venture Partners. The funds will accelerate platform development and support Phase I clinical trials for its top three lead programs starting late 2024 and early 2025. Enveda's lead program is a novel oral first-in-class anti-inflammatory agent for atopic dermatitis, showing remarkable efficacy and high safety margins in preclinical studies. A second program targets inflammatory bowel disease by inhibiting multiple cytokine signaling cascades in the gut, demonstrating robust efficacy in models. CEO Viswa Colluru highlighted the investors' confidence in the company's rapid progress and potential to advance novel medicines to patients. This follows a $51 million Series B1 equity financing in April 2023.
Apr 2023Series BKinnevik (lead); FPV Ventures; True Ventures; Henry Kravis; Dimension Capital; Wireframe Ventures$51M-Enveda Biosciences is an AI-powered drug discovery company based in Boulder, Colorado, founded in 2019 by Viswa Colluru, Ph.D., that uses nature-inspired chemistry to develop small-molecule drugs for diseases like inflammation, fibrosis, neurosensory disorders, atopic dermatitis, asthma, and inflammatory bowel disease. The company integrates artificial intelligence to characterize and screen natural compounds, accelerating discovery at roughly four times the speed of traditional methods, and has built a pipeline of 10 drug candidates, with its lead ENV-294 entering Phase 1 trials for atopic dermatitis and other inflammatory conditions in late October before the April 2023 round. In April 2023, Enveda raised $51 million in an additional equity financing round (Series B1), led by Kinnevik with participation from FPV Ventures, True Ventures, Dimension Capital, and Wireframe Ventures, adding to its prior $68 million Series B from December 2022 to reach a combined $119 million for Series B/B1. Kinnevik invested $25 million alongside partner fund Dimension in this post-quarter-end (Q1 2023) round, building on their emerging life sciences cluster. The funds were earmarked to progress multiple platform-derived molecules into clinical development for inflammation, fibrosis, and neurosensory indications. Enveda continued raising capital aggressively afterward, securing a $130 million Series C in late 2024 led by Kinnevik and FPV (with investors including Dimension Capital, Lux Capital, True Ventures, Baillie Gifford, Premji Invest, and Henry R. Kravis), followed by another $150 million Series D in 2025 led by Premji Invest (with Kinnevik participation), bringing total funding to over $500 million by mid-2025. The company advanced its lead candidate through Phase 1a successfully and into Phase 1b, planning Phase 2 trials and new IND filings across large indications affecting over 100 million US adults.
Dec 2022Series BDimension Capital (lead); Amino Collective; Possible Ventures; Hummingbird Ventures; Level Ventures; Lux Capital; FPV Ventures; True Ventures; Jazz Venture Partners; Allen & Company; Wireframe Ventures; Two Sigma Ventures$55M-Enveda Biosciences is a Boulder-based biotechnology company that uses metabolomics, machine learning, and AI-driven drug discovery to identify novel drug compounds from natural sources. The company's platform systematically translates molecules found in medicinal plants into new drugs for challenging diseases, focusing on therapeutic areas including inflammation, fibrosis, cytokine-receptor interactions, GPCRs, and the inflammasome pathway. On December 21, 2022, Enveda closed a Series B financing round totaling $68 million in combined equity and debt, led by Dimension Capital. The round included participation from multiple institutional investors: FPV Ventures, Jazz Venture Partners, Level Ventures, Amino Collective, Allen & Company, and Possible Ventures, as well as participation from all of the company's existing major investors including True Ventures, Lux Capital, Wireframe Ventures, Hummingbird Ventures, and Two Sigma Ventures. The financing brought Enveda's total capital raised to $124 million at that time. The company subsequently raised additional funding, including a Series D round of $150 million on September 4, 2025, with participation from Sanofi.
Jun 2021Series ALux Capital (lead); Bioverge; Village Global; Hummingbird Ventures; True Ventures; Catalio Capital Management; Chris Gibson; Lifeforce Capital; Wireframe Ventures; Two Sigma Ventures; Matt De Silva$51M-Enveda Biosciences, founded in 2019, is a biotechnology company using machine learning, metabolomics, and automation to explore nature's chemistry for developing next-generation small molecule therapeutics from plants and natural sources. The company aims to create the first high-resolution chemical map of the natural world, addressing the untapped 95% of natural chemical mystery to identify high-potential compounds for diseases like nonalcoholic steatohepatitis and Parkinson’s. On June 22, 2021, Enveda closed an oversubscribed $51 million Series A funding round led by Lux Capital, with participation from Two Sigma Ventures, Hummingbird Ventures, Catalio Capital Management, Lifeforce Capital, Matthew De Silva of Notable Labs, and existing investors True Ventures, Wireframe Ventures, Village Global, and Chris Gibson of Recursion. The funds are designated to scale operations, including building a new lab in Boulder, Colorado, expanding preclinical research, advancing the pipeline of interesting molecules and chemicals, and enhancing the platform's search engine capabilities. At the time, Enveda had begun mapping hundreds of medicinal plants and was positioning itself to transform natural product drug discovery, which has historically produced transformative medicines like aspirin, statins, and morphine but faced challenges in efficiency. The company plans to establish long-term roots in Boulder to attract talent and leverage local support while continuing to catalog molecules for pharmaceutical applications, noting the high failure rate (over 90%) in clinical trials for lab-discovered compounds. Later developments include additional funding rounds, with a Series D in 2025 raising $150 million at a $1.2 billion valuation, bringing cumulative funding to around $520 million, but these pertain to subsequent stages.
Aug 2020SeedTrue Ventures (lead); Village Global; Chris Gibson; Vertical Partners; Wireframe Ventures$5M-Enveda Biosciences raised a seed round of $4.9 million in December 2020. The round was led by True Ventures with participation from investors including Chris Gibson, Village Global, and Wireframe Ventures. Another source lists the seed as $4.1 million on August 11, 2020. The company uses AI and machine learning to harness nature's chemistry for small-molecule drug discovery.

Who has invested in Enveda Biosciences?

38 investors have backed Enveda Biosciences across its funding rounds, including True Ventures, FPV Ventures, Kinnevik, Lux Capital, Premji Invest and Wireframe Ventures.

Lead investors include Catalio Capital Management, Premji Invest, Sanofi, FPV Ventures, Kinnevik and 3 other investors.


Enveda Biosciences Investors

Investors in Enveda Biosciences by funding rounds participated
InvestorHQRoundsRoleFirst check
True VenturesUnited StatesSan Francisco, CA7LeadAug 2020
FPV VenturesUnited StatesSan Francisco, CA6LeadDec 2022
KinnevikSwedenStockholm5LeadApr 2023
Lux CapitalUnited StatesNew York City, NY4LeadJun 2021
Premji InvestIndiaBangalore4LeadJun 2024
Dimension CapitalUnited StatesNew York City, NY4LeadDec 2022
Wireframe VenturesUnited StatesSan Francisco, CA4ParticipantAug 2020
LingottoUnited KingdomLondon3ParticipantJun 2024
Level VenturesUnited StatesNew York City, NY3ParticipantDec 2022
Henry KravisUnited StatesNew York City, NY3ParticipantApr 2023
Baillie GiffordUnited KingdomEdinburgh2ParticipantNov 2024
Village GlobalUnited StatesLos Angeles, CA2ParticipantAug 2020
Hummingbird VenturesBelgiumBrussels2ParticipantJun 2021

This data is available for Pro users. Sign up to see all 38 Enveda Biosciences investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Enveda Biosciences Competitors

Enveda Biosciences competitors include listed companies like Genus and SoundHound, and private ones like Yitu Technology, ArsenalBio, Preferred Networks and Allen Control Systems.

Public and private companies comparable to Enveda Biosciences
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Yitu TechnologyChinaShanghaiPrivate--$2B-
GenusUnited KingdomUnited KingdomPublicly listed$880M$491M$2B2.4x
ArsenalBioUnited StatesUnited StatesPrivate--$1.9B-
Preferred NetworksJapanTokyoPrivate--$1.9B-
SoundHoundUnited StatesUnited StatesPublicly listed$169M$19M$1.9B7.4x
Allen Control SystemsUnited StatesUnited StatesPrivate--$2.2B-

Enveda Biosciences Public Comps

Enveda Biosciences is still privately-owned, but its public comps include Genus, GeneDx, SoundHound, Vazyme Biotech, Insight Lifetech, Azenta, Personalis, BGI Genomics, Shenzhen Intellifusion and Molbio Diagnostics.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Genus$880M$491M2.4x2.4x4.2x11.6x
GeneDx$428M$7M4.9x4.4x316.1x154.5x
SoundHound$169M$19M9.9x7.4x90.0x(23.3x)
Vazyme Biotech$207M$18M7.1x6.3x82.2x35.4x
Insight Lifetech$81M$18M19.1x14.1x86.2x-
Azenta$594M$35M2.4x2.3x40.8x24.8x
Personalis$70M($78M)21.8x18.7x(19.4x)(14.8x)
BGI Genomics$557M($20M)3.5x3.4x(96.6x)42.0x

This data is available for Pro users. Sign up to see all Enveda Biosciences competitors and their valuation data.

Start Free Trial

Common questions about Enveda Biosciences

When was Enveda Biosciences founded?Enveda Biosciences was founded in 2019.
Where is Enveda Biosciences headquartered?Enveda Biosciences is headquartered in Boulder, CO, United States.
Is Enveda Biosciences publicly listed?No, Enveda Biosciences is a private, VC-backed company.
What is Enveda Biosciences' valuation?Enveda Biosciences was last valued at $2B in its Series E in September 2026.
How much funding has Enveda Biosciences raised?Enveda Biosciences has raised $828M across 9 funding rounds.
What was Enveda Biosciences' last funding round?Enveda Biosciences' last funding round was a $311M Series E in September 2026, led by Catalio Capital Management.
Who are Enveda Biosciences' investors?Enveda Biosciences' investors include True Ventures, FPV Ventures, Kinnevik, Lux Capital, Premji Invest, Dimension Capital, Wireframe Ventures, Lingotto, Level Ventures, Henry Kravis and 28 others.
Which companies are comparable to Enveda Biosciences?Companies comparable to Enveda Biosciences include Yitu Technology, Genus, ArsenalBio, Preferred Networks, SoundHound and Allen Control Systems.

See companies similar to Enveda Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial